Unadjusted Confounding in the Association Between Clonal Hematopoiesis and Heart Failure After Cancer Therapy
-
By
-
Shi-Jie Zhang
-
Guiying Gao
-
June 1, 2026
-
Clinical Scorecard: The Impact of Unadjusted Confounding on the Link Between Clonal Hematopoiesis and Heart Failure Following Cancer Treatment
At a Glance
| Category | Detail |
|---|
| Condition | Clonal Hematopoiesis of Indeterminate Potential (CHIP) |
| Key Mechanisms | Association with increased risk of heart failure post-cancer therapy |
| Target Population | Cancer survivors with CHIP |
| Care Setting | Oncology and cardiology |
Key Highlights
- Significant association between CHIP and heart failure risk reported.
- Unadjusted confounders like diabetes and obesity not accounted for.
- E-value analysis suggests potential bias from unadjusted confounding.
- Hypertension's association with heart failure exceeds E-value, indicating residual confounding.
Guideline-Based Recommendations
Diagnosis
- Consider assessing CHIP in cancer survivors for heart failure risk.
Management
- Monitor heart failure symptoms in patients with CHIP post-cancer therapy.
Monitoring & Follow-up
- Evaluate for common confounders such as hypertension and diabetes.
Risks
- Unadjusted confounding may limit the interpretability of CHIP-heart failure association.
Patient & Prescribing Data
Cancer survivors with potential CHIP
Awareness of confounding factors is crucial in treatment planning.
Clinical Best Practices
- Conduct sensitivity analyses to assess confounding in clinical studies.
- Adjust for known risk factors when evaluating associations in oncology.
Related Resources & Content
